Johnson & Johnson Medical

Johnson & Johnson Medical is not clearly identifiable as a separately incorporated or consistently defined global brand in the supplied reference material. The name has historically been used in different markets and contexts for medical businesses connected with Johnson & Johnson, while the parent group’s current global medical-technology identity is Johnson & Johnson MedTech. It should therefore not be treated as a generic-pharmaceutical brand without further disambiguation. Johnson & Johnson is a United States healthcare group whose principal operating activities are organized around Innovative Medicine and MedTech. The medical-technology business develops, manufactures, and commercializes products used by hospitals, physicians, and other healthcare providers. Its areas include cardiovascular intervention, electrophysiology, heart recovery, surgery, orthopaedics, vision care, and other procedural specialties. Products are generally sold through healthcare institutions, distributors, clinicians, and specialized channels rather than through ordinary consumer retail. The medical operation’s positioning is based on clinical evidence, procedural innovation, workflow integration, physician education, and long-term relationships with hospitals and healthcare systems. Its portfolio includes technology acquired from and developed through businesses such as Biosense Webster, Abiomed, Shockwave Medical, and V-Wave. These businesses address conditions including atrial fibrillation, coronary and peripheral artery disease, heart failure, and surgical or orthopaedic needs. Recent portfolio development has emphasized cardiovascular intervention and other higher-growth medical-technology categories. Johnson & Johnson completed the acquisition of Shockwave Medical in 2024, bringing intravascular lithotripsy technology for calcified coronary and peripheral arteries into Johnson & Johnson MedTech. It also completed the acquisition of V-Wave in 2024, adding the Ventura interatrial shunt platform for heart-failure treatment. These transactions complemented the earlier acquisition of Abiomed and illustrate a strategy of concentrating resources on specialized technologies with potential to improve clinical outcomes. The supplied materials also refer to Johnson & Johnson’s broader pharmaceutical business, including the Carvykti cell therapy, Darzalex, and Tremfya. Those products belong to the group’s Innovative Medicine activities rather than establishing that “Johnson & Johnson Medical” is a pharmaceutical brand. The reference to the first direct-to-consumer Carvykti advertisement in 2025 is consequently recorded as a parent-company campaign, not as evidence that this ambiguous name represents a generic-drug portfolio. Because no single authoritative article or corporate page was supplied that defines Johnson & Johnson Medical as a distinct legal entity, product brand, or historical division, this entry preserves the name while flagging it for review. A future edition should determine whether the intended subject is Johnson & Johnson MedTech, a national subsidiary formerly using the Johnson & Johnson Medical name, or another Johnson & Johnson healthcare business.

The supplied evidence does not establish a distinct founding date, legal incorporation, or continuous corporate history for a standalone entity called Johnson & Johnson Medical. The name appears to function as an umbrella or regional designation connected with Johnson & Johnson’s healthcare and medical businesses. In the group’s current structure, the closest identifiable global subject is Johnson & Johnson MedTech, the operating organization responsible for medical technologies. Johnson & Johnson’s medical activities developed alongside the wider company’s expansion from healthcare products into hospital technologies, surgery, orthopaedics, cardiovascular care, electrophysiology, and vision care. Over time, the business combined internal research and development with acquisitions of specialist companies. This model allowed Johnson & Johnson to enter technically demanding categories where products require regulatory approval, clinical evidence, physician training, and hospital adoption. Cardiovascular technology has become a particularly visible part of the modern medical portfolio. Abiomed expanded the group’s heart-recovery capabilities, while Biosense Webster provides electrophysiology technologies used in the treatment of cardiac rhythm disorders. In 2024, Johnson & Johnson completed its acquisition of Shockwave Medical. Shockwave’s intravascular lithotripsy system uses sonic-pressure technology to modify calcified arterial plaque and is intended for coronary and peripheral vascular procedures. The transaction placed Shockwave within Johnson & Johnson MedTech and broadened the group’s cardiovascular-intervention presence. Later in 2024, Johnson & Johnson completed the acquisition of V-Wave. The company’s Ventura interatrial shunt was designed as a minimally invasive approach for selected heart-failure patients. V-Wave became part of Johnson & Johnson MedTech, adding a structural-heart and heart-failure platform to the group’s cardiovascular strategy. The parent group has also reorganized its wider portfolio. Consumer-health activities were separated into a distinct company, while Johnson & Johnson continued to focus on Innovative Medicine and MedTech. This reorganization makes it especially important to distinguish the ambiguous “Johnson & Johnson Medical” label from both the pharmaceutical business and consumer brands historically associated with Johnson & Johnson. Marketing in the medical business is primarily professional and evidence based. It uses clinical data, procedure demonstrations, healthcare-professional education, hospital relationships, and digital resources. The supplied material describes broader Johnson & Johnson campaigns involving physician outreach, patient education, real-world evidence, and specialized digital engagement. These approaches are relevant to the group’s healthcare model, but they do not prove that every campaign was run under a separate Johnson & Johnson Medical brand. The available material does not support a reliable account of a standalone “Johnson & Johnson Medical” brand’s founding, leadership succession, product catalog, or financial performance. The subject should therefore remain marked for review until a precise national subsidiary, historical division, or intended MedTech article is identified.

1. 2024Shockwave Medical acquisition completed

   Shockwave Medical became part of Johnson & Johnson MedTech, adding intravascular lithotripsy technology for coronary and peripheral artery disease.

   Source
2. 2024V-Wave acquisition completed

   V-Wave joined Johnson & Johnson MedTech with its Ventura interatrial shunt platform for heart-failure treatment.

   Source
3. 2024Proteologix acquisition completed

   Johnson & Johnson added Proteologix’s early bispecific-antibody pipeline for immune-mediated diseases to its Innovative Medicine activities.

   Source

Evidence-led medical technology for hospitals and healthcare professionals, with emphasis on cardiovascular intervention, procedural innovation, clinical education, and technology integration.

• Shockwave intravascular lithotripsyCardiovascular intervention

  A catheter-based platform that uses sonic-pressure waves to disrupt or modify calcified plaque in arteries. It is used in coronary and peripheral vascular intervention and became part of Johnson & Johnson MedTech through the acquisition of Shockwave Medical.

• Ventura Interatrial ShuntHeart-failure technology

  An implantable interatrial shunt developed by V-Wave for minimally invasive treatment approaches in heart failure. The platform entered Johnson & Johnson MedTech when the V-Wave acquisition was completed in 2024.

• Biosense Webster electrophysiology systemsElectrophysiology

  Mapping, navigation, ablation, and catheter technologies used by specialists to diagnose and treat cardiac rhythm disorders, including atrial fibrillation. Biosense Webster is part of Johnson & Johnson’s MedTech portfolio.

• Abiomed heart-recovery technologiesCardiac support

  Mechanical circulatory-support technologies associated with Abiomed and used in selected acute heart-failure and cardiac-procedure settings. Abiomed forms part of Johnson & Johnson’s cardiovascular medical-technology activities.

• 2025Carvykti direct-to-consumer streaming campaign

  United States

  Johnson & Johnson tested its first direct-to-consumer advertising for Carvykti, a CAR-T therapy for multiple myeloma, using streaming services to raise awareness among patients who may not be treated at specialist academic centers.

  Outcome. The campaign was presented as a sign of confidence that manufacturing capacity could support additional demand after earlier supply limitations.

  Source
• 2020Data-driven professional advertising for Listerine

  United States

  Johnson & Johnson used behavioral analysis of healthcare professionals to target digital advertising intended to encourage recommendations of the Listerine dental brand.

  Outcome. The cited case study reported professional-audience engagement substantially above an industry benchmark.

  Source

• 2024Acquire Shockwave MedicalM&A

  Johnson & Johnson sought to strengthen its cardiovascular-intervention portfolio with Shockwave’s intravascular lithotripsy technology.

  What changed. The acquisition was completed and Shockwave began operating as a business unit within Johnson & Johnson MedTech.

  Aftermath. The transaction expanded the group’s cardiovascular platforms alongside heart-recovery and electrophysiology businesses.

  Source
• 2024Acquire V-WaveM&A

  The transaction was intended to deepen Johnson & Johnson MedTech’s presence in structural heart and heart-failure care.

  What changed. Johnson & Johnson completed the acquisition of V-Wave and placed it within Johnson & Johnson MedTech.

  Aftermath. The Ventura interatrial shunt became part of the company’s developing heart-failure technology portfolio.

  Source

• 2025Johnson & Johnson introduced direct-to-consumer advertising for Carvykti

  The company tested streaming advertising for Carvykti, a CAR-T therapy for multiple myeloma, to broaden awareness beyond specialist treatment centers. The campaign also indicated increased confidence in manufacturing capacity after earlier supply constraints.

  CampaignProduct launch
  Source
• 2024Johnson & Johnson completed the acquisition of Shockwave Medical

  Shockwave Medical became a business unit within Johnson & Johnson MedTech. Its intravascular lithotripsy platform expanded Johnson & Johnson’s cardiovascular-intervention portfolio.

  M&A
  Source
• 2024Johnson & Johnson completed the acquisition of V-Wave

  V-Wave joined Johnson & Johnson MedTech, bringing the Ventura interatrial shunt platform and strengthening the group’s focus on heart-failure technologies.

  M&A
  Source
• 2024Johnson & Johnson completed the acquisition of Proteologix

  Proteologix, a biotechnology company developing bispecific antibodies for immune-mediated diseases, was acquired by Johnson & Johnson. This transaction relates to Innovative Medicine rather than the medical-device business.

  M&A
  Source

1. Johnson & Johnson Completes Acquisition of Shockwave Medical
2. Johnson & Johnson Completes Acquisition of V-Wave
3. Johnson & Johnson completes acquisition of Proteologix, Inc.
4. J&J tests direct CAR-T marketing with first Carvykti ad
5. Data-driven professional advertising for Listerine